Bone Therapeutics announces results of Annual General Meeting
Significantly strengthened its Board of Directors with appointment of Gloria Matthews as Independent Director
Shareholders also approved all other resolutions
Gosselies, Belgium, 12 June 2019, 6pm CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapeutics to address high unmet medical needs in orthopaedics and bone diseases, announces the results of its Annual General Meeting (AGM) held today at the Company’s headquarters in Gosselies.
The resolutions approved today included the appointment of Gloria Matthews, DVM(1), PhD, DACVS(2), an American citizen, as Independent Director. Gloria has more than 20 years of research and clinical experience in orthopaedics, osteoarthritis, rheumatology and cartilage repair with extensive expertise in medical devices, biologicals, and regenerative medicine. She has a strong track record of supporting life sciences companies to grow and evolve from start-up stage to fully integrated biopharma companies and has built an impressive business and medical network over the years. She was Senior Vice President of MiMedx, a biopharma company focused on the development and commercialisation of regenerative and therapeutic biologicals in wound care, and spine and sports medicine. Prior to that, she was Chief Medical Officer of the restorative cell therapy company Histogenics and Senior Director of Orthopaedics at Genzyme, a Sanofi company.
In addition to the appointment of Gloria Matthews, the AGM acknowledged the resignation of Michel Helbig de Balzac from the Board of Directors as well as the end of the mandates of Dirk Dembski and Roland Baron. The changes in Board composition are in line with the company strategy to increase diversity in both gender and expertise. The Board of Directors now comprises seven members, of whom two are women.
Welcoming Gloria Matthews to the Board, Jean Stéphenne, Chairman, said: "We are very pleased to have someone of Gloria’s calibre joining our Board of Directors. We are convinced that her network, proven track record and disease relevant in-depth expertise and strategic insights will be of important value as we enter the next stage for the Company and further advance our unique product pipeline towards Phase III clinical development. I would also like to personally thank Michel, Roland and Dirk for their invaluable support, dedication and leadership in transforming the Company into a leading biotech company focused on innovative treatment solutions in orthopaedics and bone diseases.”
Gloria Matthews commented: “I am convinced of the Company’s potential to revolutionize treatment options in orthopaedics and bone diseases, and to significantly improve current standard of care. Having observed the Company’s progress over the past 2 years, I am excited to now play a role in the acceleration of this growth. I am therefore delighted to join the Board and I look forward to working with the team to execute on the long-term growth strategy and to contributing to the Company’s future successes.”
The final results of the Annual General Meeting will be made available on the Company’s website.
(1) Doctor of Veterinary Medicine
(2) Doctor American College of Veterinary Surgeons